Saturday 17 October 2026
Export RNTX’s income statement to Excel — free account
Rein Therapeutics Inc.
RNTX Healthcare Biotechnology
In the quarter to June 2026, EPS grew 64.3% and free cash flow fell 34.6%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.59
0.04
−6.35%
Follow RNTX
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Dec '18 | Dec '17 | Dec '16 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
0.70 | 2.38 | 4.17 | 6.46 | 10.69 | 4.12 | 3.35 | 4.05 | 10.60 | 5.18 |
Net Debt/EBITDA |
0.15 | 0.46 | 1.08 | 0.77 | 1.75 | 0.69 | 0.44 | 0.48 | 2.21 | 1.16 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 2.37% | 19.01% | 17.62% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.03 | 0.31 | 0.27 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.39 | 0.35 | 1.26 | 0.91 | 0.91 | 0.97 | 0.90 | 0.89 | 0.91 | 0.83 |
Capex/Depreciation |
0.00 | 0.00 | 0.28 | 0.00 | (0.25) | 1.32 | 1.99 | 126.37 | 6.17 | 0.00 |
| 533.38% | (772.80%) | (123.34%) | (87.42%) | (93.33%) | (150.00%) | (164.77%) | (93.62%) | 70.76% | 56.86% | |
| (115.51%) | (74.77%) | (24.58%) | (77.54%) | (80.73%) | (98.83%) | (103.44%) | (76.02%) | (60.62%) | (165.28%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | (674.20%) | (472.26%) | 0.00% | 0.00% |
Return on Tangible Assets |
2,689.91% | (795.08%) | (113.18%) | (147.25%) | (59.74%) | (170.88%) | (209.69%) | (133.14%) | (48.08%) | (106.37%) |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.82 | 0.78 | 0.81 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Free Cash Flow per Share |
(0.76) | (1.24) | (4.30) | (5.48) | (5.37) | (11.63) | (21.70) | (43.90) | (55.54) | (698.33) |
Cash per Share |
0.13 | 0.72 | 3.77 | 4.69 | 10.35 | 8.26 | 14.92 | 28.12 | 136.59 | 964.65 |
Shareholders Equity per Share |
(1.10) | 0.52 | 1.50 | 4.10 | 9.89 | 6.98 | 13.08 | 26.60 | 128.42 | (5,200.28) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(1.10) | 0.52 | 1.50 | 4.10 | 9.89 | 6.98 | 13.08 | 26.60 | 128.42 | (5,200.28) |
Free Cash Flow |
(19.36) | (22.29) | (19.77) | (24.86) | (23.84) | (20.27) | (26.62) | (32.35) | (20.67) | (15.01) |
Working Capital |
(1.85) | 7.91 | 13.88 | 18.49 | 43.67 | 12.37 | 13.71 | 16.41 | 46.95 | 17.00 |
Capital Expenditures |
— | — | 0.04 | — | (0.09) | 0.20 | (0.15) | (4.42) | (0.14) | — |
Net Current Asset Value |
(47.92) | (39.15) | (80.85) | 18.49 | 43.60 | 12.15 | 9.13 | 11.06 | 46.95 | (112.75) |
| Other line items | ||||||||||
Quick Ratio |
0.52 | 2.24 | 3.95 | 6.28 | 10.19 | 3.64 | 3.13 | 3.86 | 10.39 | 5.09 |
Depreciation/Fixed assets |
0.00 | 37,063.00 | 7.95 | (0.56) | 2.82 | 10.27 | (0.26) | 0.00 | (0.15) | 2.17 |
Cash ROIC |
77.84% | (100.18%) | (81.59%) | (62.33%) | (26.54%) | (75.23%) | (67.61%) | (70.84%) | (20.96%) | 16.49% |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(0.76) | (1.24) | (4.31) | (5.48) | (5.35) | (11.74) | (21.58) | (37.90) | (55.16) | (698.33) |
Capex per Share |
0.00 | 0.00 | 0.01 | 0.00 | (0.02) | 0.12 | (0.12) | (6.00) | (0.38) | 0.00 |
Average Payables |
2.44 | 1.05 | 1.46 | 1.47 | 1.40 | 1.52 | 1.59 | 1.67 | 1.79 | 1.79 |
Average Assets |
43.17 | 84.10 | 64.01 | 35.24 | 32.41 | 21.41 | 28.39 | 41.50 | 37.35 | 11.01 |
Average Common Equity |
(9.35) | 8.14 | 12.76 | 31.26 | 28.03 | 14.11 | 17.82 | 33.70 | (32.00) | (32.00) |
Capex to Sales |
— | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — |
Columns are period end dates